Shanghai Fosun Pharmaceutical(Group) Co.,Ltd.’s Net Profit Rose 11% in First Half of 2023

Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海复星医药(集团)股份有限公司) (600196.SH) reported a net profit of 2 billion yuan in the first half of 2023, up 11% year-on-year.

Meanwhile, the company posted 21.4 billion yuan in revenue, up 0.2% year-on-year.

At the end of the reporting period, it had 112.1 billion yuan in total assets and 56.7 billion yuan in total liabilities, with a liability-to-asset ratio of 50.6%.